{
    "info": {
        "nct_id": "NCT05171049",
        "official_title": "A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE",
        "inclusion_criteria": "* Male or female subjects ≥18 years old or other legal maturity age according to the country of residence\n* Confirmed diagnosis of cancer (by histology, adequate imaging modality), other than basal-cell or squamous-cell carcinoma of the skin alone with one of the following:\n\n  * Active cancer, defined as either locally active, regionally invasive, or metastatic cancer at the time of randomization and/or\n  * Currently receiving or having received anticancer therapy (radiotherapy, chemotherapy, hormonal therapy, any kind of targeted therapy or any other anticancer therapy) in the last 6 months.\n* Confirmed symptomatic or incidental proximal lower limb deep vein thrombosis (DVT) (i.e., popliteal, femoral, iliac, and/or inferior vena cava [IVC] thrombosis) and/or a confirmed symptomatic pulmonary embolism (PE), or an incidental PE in a segmental, or larger pulmonary artery.\n\nPatients are eligible within 120 hours from diagnosis of the qualifying VTE\n\n* Anticoagulation therapy with a therapeutic dose of DOAC for at least 6 months is indicated\n* Able to provide written informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Thrombectomy, insertion of a caval filter or use of a fibrinolytic agent to treat the current (index) DVT and/or PE\n* More than 120 hours of pre-treatment with therapeutic doses of UFH, LMWH, fondaparinux, DOAC, or other anticoagulants\n* An indication to continue treatment with therapeutic doses of an anticoagulant other than that VTE treatment prior to randomization (e.g., atrial fibrillation [AF], mechanical heart valve, prior VTE)\n* Platelet count <50,000/mm3 at the screening visit\n* PE leading to hemodynamic instability (blood pressure [BP] <90 mmHg or shock)\n* Acute ischemic or hemorrhagic stroke or intracranial hemorrhage within the 4 weeks preceding screening\n* Brain trauma or a cerebral or spinal cord surgery or spinal procedures such as lumbar puncture or epidural/spinal anesthesia within 4 weeks of screening\n* Need for aspirin in a dosage of >100 mg/day or any other antiplatelet agent alone or in combination with aspirin\n* Primary brain cancer or untreated intracranial metastases at baseline\n* Acute myeloid or lymphoid leukemia\n* Bleeding requiring medical attention at the time of randomization or in the preceding 4 weeks\n* Planned brain, spinal cord, cardiac, vascular, major thoracic and/or major abdominal surgery in the 4 weeks following randomization\n* Eastern Cooperative Oncology Group (ECOG) performance status of 3 or 4 at screening\n* Life expectancy <3 months at randomization\n* Calculated creatinine clearance (CrCl) <30 mL/min (Cockcroft-Gault equation) at the screening visit\n* Hemoglobin <8 g/dL at the screening visit\n* Acute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase (ALT) ≥3 x and/or bilirubin ≥2 x upper limit of normal (ULN) at the screening visit in absence of clinical explanation\n* Uncontrolled hypertension (systolic BP>180 mm Hg or diastolic BP >100 mm Hg despite antihypertensive treatment)\n* Women of child-bearing potential (WOCBP) who are unwilling or unable to use highly effective contraceptive measures during the study from screening up to 3 days after last treatment of apixaban or 100 days after administration of abelacimab (See Section 5.3.6. for highly effective contraceptive measures)\n* Sexually active males with sexual partners of childbearing potential must agree to use a condom or other reliable contraceptive measure up to 3 days after last treatment of apixaban or 100 days after administration of abelacimab\n* Pregnant or breast-feeding women\n* Patients known to be receiving strong dual inducers or inhibitors of both CYP3A4 and P gp\n* History of hypersensitivity to any of the study drugs (including apixaban) or excipients, to drugs of similar chemical classes, or any contraindication listed in the label for apixaban\n* Subjects with any condition that in the Investigator's judgement would place the subject at increased risk of harm if he/she participated in the study\n* Use of other investigational (not registered) drugs within 5 half-lives prior to enrollment or until the expected pharmacodynamic(s) (PD) effect has returned to baseline, whichever is longer. Participation in academic non-interventional studies or interventional studies, comprising testing different strategies or different combinations of registered drugs is permitted",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Able to provide written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Able to provide written informed consent",
                    "criterion": "ability to provide written informed consent",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Anticoagulation therapy with a therapeutic dose of DOAC for at least 6 months is indicated",
            "criterions": [
                {
                    "exact_snippets": "Anticoagulation therapy with a therapeutic dose of DOAC for at least 6 months is indicated",
                    "criterion": "anticoagulation therapy with DOAC",
                    "requirements": [
                        {
                            "requirement_type": "indication",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": "therapeutic"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Confirmed symptomatic or incidental proximal lower limb deep vein thrombosis (DVT) (i.e., popliteal, femoral, iliac, and/or inferior vena cava [IVC] thrombosis) and/or a confirmed symptomatic pulmonary embolism (PE), or an incidental PE in a segmental, or larger pulmonary artery.",
            "criterions": [
                {
                    "exact_snippets": "Confirmed symptomatic or incidental proximal lower limb deep vein thrombosis (DVT) (i.e., popliteal, femoral, iliac, and/or inferior vena cava [IVC] thrombosis)",
                    "criterion": "proximal lower limb deep vein thrombosis (DVT)",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": [
                                "symptomatic",
                                "incidental"
                            ]
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "popliteal",
                                "femoral",
                                "iliac",
                                "inferior vena cava"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmed symptomatic pulmonary embolism (PE)",
                    "criterion": "pulmonary embolism (PE)",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "incidental PE in a segmental, or larger pulmonary artery",
                    "criterion": "pulmonary embolism (PE)",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "incidental"
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": "segmental or larger pulmonary artery"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Currently receiving or having received anticancer therapy (radiotherapy, chemotherapy, hormonal therapy, any kind of targeted therapy or any other anticancer therapy) in the last 6 months.",
            "criterions": [
                {
                    "exact_snippets": "Currently receiving or having received anticancer therapy (radiotherapy, chemotherapy, hormonal therapy, any kind of targeted therapy or any other anticancer therapy) in the last 6 months.",
                    "criterion": "anticancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "exposure",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Confirmed diagnosis of cancer (by histology, adequate imaging modality), other than basal-cell or squamous-cell carcinoma of the skin alone with one of the following:",
            "criterions": [
                {
                    "exact_snippets": "Confirmed diagnosis of cancer (by histology, adequate imaging modality)",
                    "criterion": "cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histology",
                                "adequate imaging modality"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "other than basal-cell or squamous-cell carcinoma of the skin alone",
                    "criterion": "cancer type",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": [
                                "basal-cell carcinoma of the skin alone",
                                "squamous-cell carcinoma of the skin alone"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active cancer, defined as either locally active, regionally invasive, or metastatic cancer at the time of randomization and/or",
            "criterions": [
                {
                    "exact_snippets": "Active cancer, defined as either locally active, regionally invasive, or metastatic cancer at the time of randomization",
                    "criterion": "cancer activity status",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": [
                                "locally active",
                                "regionally invasive",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "time",
                            "expected_value": "at the time of randomization"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male or female subjects ≥18 years old or other legal maturity age according to the country of residence",
            "criterions": [
                {
                    "exact_snippets": "Male or female subjects",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "allowed_values",
                            "expected_value": [
                                "male",
                                "female"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "≥18 years old or other legal maturity age according to the country of residence",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "legal maturity age",
                            "expected_value": "according to the country of residence"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Patients are eligible within 120 hours from diagnosis of the qualifying VTE",
            "criterions": [
                {
                    "exact_snippets": "within 120 hours from diagnosis of the qualifying VTE",
                    "criterion": "time from diagnosis of qualifying VTE",
                    "requirements": [
                        {
                            "requirement_type": "maximum time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 120,
                                "unit": "hours"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Primary brain cancer or untreated intracranial metastases at baseline",
            "criterions": [
                {
                    "exact_snippets": "Primary brain cancer",
                    "criterion": "primary brain cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "untreated intracranial metastases at baseline",
                    "criterion": "intracranial metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "at baseline"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelet count <50,000/mm3 at the screening visit",
            "criterions": [
                {
                    "exact_snippets": "Platelet count <50,000/mm3 at the screening visit",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50000,
                                "unit": "mm3"
                            }
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "at the screening visit"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Need for aspirin in a dosage of >100 mg/day or any other antiplatelet agent alone or in combination with aspirin",
            "criterions": [
                {
                    "exact_snippets": "Need for aspirin in a dosage of >100 mg/day",
                    "criterion": "aspirin dosage",
                    "requirements": [
                        {
                            "requirement_type": "dosage",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "mg/day"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any other antiplatelet agent alone or in combination with aspirin",
                    "criterion": "antiplatelet agent use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Thrombectomy, insertion of a caval filter or use of a fibrinolytic agent to treat the current (index) DVT and/or PE",
            "criterions": [
                {
                    "exact_snippets": "Thrombectomy ... to treat the current (index) DVT and/or PE",
                    "criterion": "thrombectomy for current DVT and/or PE",
                    "requirements": [
                        {
                            "requirement_type": "treatment usage",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "insertion of a caval filter ... to treat the current (index) DVT and/or PE",
                    "criterion": "caval filter insertion for current DVT and/or PE",
                    "requirements": [
                        {
                            "requirement_type": "treatment usage",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "use of a fibrinolytic agent to treat the current (index) DVT and/or PE",
                    "criterion": "fibrinolytic agent use for current DVT and/or PE",
                    "requirements": [
                        {
                            "requirement_type": "treatment usage",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant or breast-feeding women",
            "criterions": [
                {
                    "exact_snippets": "Pregnant ... women",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breast-feeding women",
                    "criterion": "breast-feeding status",
                    "requirements": [
                        {
                            "requirement_type": "breast-feeding",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Acute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase (ALT) ≥3 x and/or bilirubin ≥2 x upper limit of normal (ULN) at the screening visit in absence of clinical explanation",
            "criterions": [
                {
                    "exact_snippets": "Acute hepatitis",
                    "criterion": "acute hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic active hepatitis",
                    "criterion": "chronic active hepatitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "liver cirrhosis",
                    "criterion": "liver cirrhosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase (ALT) ≥3 x ... upper limit of normal (ULN) at the screening visit",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "bilirubin ≥2 x upper limit of normal (ULN) at the screening visit",
                    "criterion": "bilirubin level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bleeding requiring medical attention at the time of randomization or in the preceding 4 weeks",
            "criterions": [
                {
                    "exact_snippets": "Bleeding requiring medical attention at the time of randomization",
                    "criterion": "bleeding",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "requiring medical attention"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at the time of randomization"
                        }
                    ]
                },
                {
                    "exact_snippets": "Bleeding requiring medical attention ... in the preceding 4 weeks",
                    "criterion": "bleeding",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "requiring medical attention"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "in the preceding 4 weeks"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* An indication to continue treatment with therapeutic doses of an anticoagulant other than that VTE treatment prior to randomization (e.g., atrial fibrillation [AF], mechanical heart valve, prior VTE)",
            "criterions": [
                {
                    "exact_snippets": "An indication to continue treatment with therapeutic doses of an anticoagulant other than that VTE treatment prior to randomization (e.g., atrial fibrillation [AF], mechanical heart valve, prior VTE)",
                    "criterion": "indication for anticoagulant therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "indication type",
                            "expected_value": [
                                "atrial fibrillation",
                                "mechanical heart valve",
                                "prior VTE"
                            ]
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": "VTE treatment prior to randomization"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients known to be receiving strong dual inducers or inhibitors of both CYP3A4 and P gp",
            "criterions": [
                {
                    "exact_snippets": "Patients known to be receiving strong dual inducers or inhibitors of both CYP3A4 and P gp",
                    "criterion": "concomitant medication (CYP3A4 and P gp inducers/inhibitors)",
                    "requirements": [
                        {
                            "requirement_type": "use of strong dual inducers or inhibitors of both CYP3A4 and P gp",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled hypertension (systolic BP>180 mm Hg or diastolic BP >100 mm Hg despite antihypertensive treatment)",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension (systolic BP>180 mm Hg or diastolic BP >100 mm Hg despite antihypertensive treatment)",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "systolic BP>180 mm Hg ... despite antihypertensive treatment",
                    "criterion": "systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 180,
                                "unit": "mm Hg"
                            }
                        },
                        {
                            "requirement_type": "response to antihypertensive treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "diastolic BP >100 mm Hg ... despite antihypertensive treatment",
                    "criterion": "diastolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "mm Hg"
                            }
                        },
                        {
                            "requirement_type": "response to antihypertensive treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Brain trauma or a cerebral or spinal cord surgery or spinal procedures such as lumbar puncture or epidural/spinal anesthesia within 4 weeks of screening",
            "criterions": [
                {
                    "exact_snippets": "Brain trauma ... within 4 weeks of screening",
                    "criterion": "brain trauma",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "cerebral or spinal cord surgery ... within 4 weeks of screening",
                    "criterion": "cerebral or spinal cord surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "spinal procedures such as lumbar puncture or epidural/spinal anesthesia within 4 weeks of screening",
                    "criterion": "spinal procedures (lumbar puncture or epidural/spinal anesthesia)",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PE leading to hemodynamic instability (blood pressure [BP] <90 mmHg or shock)",
            "criterions": [
                {
                    "exact_snippets": "PE leading to hemodynamic instability",
                    "criterion": "pulmonary embolism (PE)",
                    "requirements": [
                        {
                            "requirement_type": "consequence",
                            "expected_value": "hemodynamic instability"
                        }
                    ]
                },
                {
                    "exact_snippets": "blood pressure [BP] <90 mmHg",
                    "criterion": "blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 90,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "shock",
                    "criterion": "shock",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects with any condition that in the Investigator's judgement would place the subject at increased risk of harm if he/she participated in the study",
            "criterions": [
                {
                    "exact_snippets": "any condition that in the Investigator's judgement would place the subject at increased risk of harm if he/she participated in the study",
                    "criterion": "any condition increasing risk of harm (per Investigator's judgement)",
                    "requirements": [
                        {
                            "requirement_type": "risk of harm (per Investigator's judgement)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Planned brain, spinal cord, cardiac, vascular, major thoracic and/or major abdominal surgery in the 4 weeks following randomization",
            "criterions": [
                {
                    "exact_snippets": "Planned brain ... surgery in the 4 weeks following randomization",
                    "criterion": "planned brain surgery",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks after randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Planned ... spinal cord ... surgery in the 4 weeks following randomization",
                    "criterion": "planned spinal cord surgery",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks after randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Planned ... cardiac ... surgery in the 4 weeks following randomization",
                    "criterion": "planned cardiac surgery",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks after randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Planned ... vascular ... surgery in the 4 weeks following randomization",
                    "criterion": "planned vascular surgery",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks after randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Planned ... major thoracic ... surgery in the 4 weeks following randomization",
                    "criterion": "planned major thoracic surgery",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks after randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Planned ... major abdominal surgery in the 4 weeks following randomization",
                    "criterion": "planned major abdominal surgery",
                    "requirements": [
                        {
                            "requirement_type": "timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks after randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of other investigational (not registered) drugs within 5 half-lives prior to enrollment or until the expected pharmacodynamic(s) (PD) effect has returned to baseline, whichever is longer. Participation in academic non-interventional studies or interventional studies, comprising testing different strategies or different combinations of registered drugs is permitted",
            "criterions": [
                {
                    "exact_snippets": "Use of other investigational (not registered) drugs within 5 half-lives prior to enrollment or until the expected pharmacodynamic(s) (PD) effect has returned to baseline, whichever is longer.",
                    "criterion": "use of other investigational (not registered) drugs",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "PD effect",
                            "expected_value": "returned to baseline"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of child-bearing potential (WOCBP) who are unwilling or unable to use highly effective contraceptive measures during the study from screening up to 3 days after last treatment of apixaban or 100 days after administration of abelacimab (See Section 5.3.6. for highly effective contraceptive measures)",
            "criterions": [
                {
                    "exact_snippets": "Women of child-bearing potential (WOCBP)",
                    "criterion": "sex and reproductive potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "reproductive_potential",
                            "expected_value": "child-bearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "unwilling or unable to use highly effective contraceptive measures during the study from screening up to 3 days after last treatment of apixaban or 100 days after administration of abelacimab",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "willingness to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability to use contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraceptive effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "duration of use",
                            "expected_value": [
                                "from screening up to 3 days after last treatment of apixaban",
                                "from screening up to 100 days after administration of abelacimab"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy <3 months at randomization",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy <3 months at randomization",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin <8 g/dL at the screening visit",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin <8 g/dL at the screening visit",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 8,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* More than 120 hours of pre-treatment with therapeutic doses of UFH, LMWH, fondaparinux, DOAC, or other anticoagulants",
            "criterions": [
                {
                    "exact_snippets": "More than 120 hours of pre-treatment with therapeutic doses of UFH, LMWH, fondaparinux, DOAC, or other anticoagulants",
                    "criterion": "pre-treatment with anticoagulants",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 120,
                                "unit": "hours"
                            }
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": "therapeutic"
                        },
                        {
                            "requirement_type": "anticoagulant_type",
                            "expected_value": [
                                "UFH",
                                "LMWH",
                                "fondaparinux",
                                "DOAC",
                                "other anticoagulants"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Calculated creatinine clearance (CrCl) <30 mL/min (Cockcroft-Gault equation) at the screening visit",
            "criterions": [
                {
                    "exact_snippets": "Calculated creatinine clearance (CrCl) <30 mL/min (Cockcroft-Gault equation) at the screening visit",
                    "criterion": "calculated creatinine clearance (CrCl)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault equation"
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "screening visit"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Acute myeloid or lymphoid leukemia",
            "criterions": [
                {
                    "exact_snippets": "Acute myeloid or lymphoid leukemia",
                    "criterion": "leukemia type",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "acute myeloid leukemia",
                                "acute lymphoid leukemia"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Sexually active males with sexual partners of childbearing potential must agree to use a condom or other reliable contraceptive measure up to 3 days after last treatment of apixaban or 100 days after administration of abelacimab",
            "criterions": [
                {
                    "exact_snippets": "Sexually active males",
                    "criterion": "sexually active male",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "male"
                        },
                        {
                            "requirement_type": "sexual activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "sexual partners of childbearing potential",
                    "criterion": "sexual partner childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "partner childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use a condom or other reliable contraceptive measure up to 3 days after last treatment of apixaban",
                    "criterion": "contraceptive use after apixaban",
                    "requirements": [
                        {
                            "requirement_type": "contraceptive use duration after apixaban",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use a condom or other reliable contraceptive measure up to ... 100 days after administration of abelacimab",
                    "criterion": "contraceptive use after abelacimab",
                    "requirements": [
                        {
                            "requirement_type": "contraceptive use duration after abelacimab",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Acute ischemic or hemorrhagic stroke or intracranial hemorrhage within the 4 weeks preceding screening",
            "criterions": [
                {
                    "exact_snippets": "Acute ischemic or hemorrhagic stroke ... within the 4 weeks preceding screening",
                    "criterion": "acute ischemic stroke",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Acute ischemic or hemorrhagic stroke ... within the 4 weeks preceding screening",
                    "criterion": "acute hemorrhagic stroke",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "intracranial hemorrhage within the 4 weeks preceding screening",
                    "criterion": "intracranial hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status of 3 or 4 at screening",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 3 or 4 at screening",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* History of hypersensitivity to any of the study drugs (including apixaban) or excipients, to drugs of similar chemical classes, or any contraindication listed in the label for apixaban",
            "criterions": [
                {
                    "exact_snippets": "History of hypersensitivity to any of the study drugs (including apixaban)",
                    "criterion": "hypersensitivity to study drugs",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity ... to excipients",
                    "criterion": "hypersensitivity to excipients",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity ... to drugs of similar chemical classes",
                    "criterion": "hypersensitivity to drugs of similar chemical classes",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any contraindication listed in the label for apixaban",
                    "criterion": "contraindication to apixaban (per label)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}